support@mellalta.com   +1 (304) 306-0723

Eleven Global Partners one Technology: Halozyme ENHANZE technology

Halozyme, is a biopharmaceutical company which provides innovative and disruptive solutions for novel and well-established therapies. Halozyme with its world class technology have partnered with leading global players to improve patient’s treatment outcomes. Halozyme’s ENHANZE technology: […]

Read More

Familial chylomicronemia syndrome (FCS)- Refile NDA for Volanesorsen (WAYLIVRA) with USFDA in H2 2020

Volanesorsen-WAYLIVRA-Familial-chylomicronemia-syndrome-FCS-in-H2-2020

Volanesorsen (WAYLIVRA) is the leading drug in Familial chylomicronemia syndrome (FCS) space globally., developed by Ionis & Akcea Therapeutics. Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by mutations in the lipoprotein […]

Read More

Diffuse Intrinsic Pontine Glioma (DIPG) -How Aggressive the Disease Pipeline is?

Diffuse Intrinsic Pontine Glioma

Ziopharm Oncology recently received the rare paediatric disease for their gene therapy for Diffuse Intrinsic Pontine Glioma (DIPG). The company has the ability to deliver DNA and stimulate a controlled therapeutic immune response with their […]

Read More

TG Therapeutics’ highly potential pipeline, is poised to fire up the market in the year 2021

TG Therapeutics umbralisib PDUFA date MZL and FL Marginal Zone Lymphoma (MZL) Follicular Lymphoma (FL)

TG Therapeutic (TGTX) is a biotechnology company focused on cancer & autoimmune disease with registration programs ongoing in: Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma (MZL) Follicular Lymphoma (FL) Multiple Sclerosis (MS) In June 2020 […]

Read More

High Risk Myelodysplastic syndromes (HR-MDS) –Takeda, Gilead, Onconova Therapeutics & MEI Pharma

High Risk Myelodysplastic syndromes (MDS)-KEY DEVELOPMENTS

Myelodysplastic syndromes (MDS) is a rare form of bone marrow-related cancer caused by mutation of one or more genes that control development of blood cells. This cancer most commonly affects older patients, with the median […]

Read More

Pneumococcal Vaccine (Prevnar 13 and Pneumovax 23) ACIP Guidelines’ Impact on KOLs and PCP; UNKNOWN VS KNOWNS-a study by Mellalta Meets 2020

Pneumococcal Vaccination ACIP Impact

Mellalta Meets conducted a survey in the United States to understand doctors’ and KOL’s concerns and opinion regarding the impact of recent ACIP guidelines on Pneumococcal Vaccine prescriptions (Prevnar 13 and Pneumovax 23) What is answered! […]

Read More

Actinium’s Multi-billion Dollar Market for Targeted Conditioning with their revolutionary Antibody Warhead Enabling (AWE) platform!

Actinium Pharmaceuticals’ Antibody Warhead Enabling (AWE) Future Opportunities

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology. The technology enables the development of breakthrough Antibody Radiation-Conjugates (ARCs), that combine the targeting ability of antibodies with the […]

Read More

Development & Marketing Strategy behind, Daiichi Sankyo’s DS-1062, $6 billion deal with AstraZeneca

Daiichi Sankyo unveiled about the collaboration between them and AstraZeneca for antibody drug conjugate, DS-1062. This news has created absolute havoc in the Pharma market. As per the agreement, AstraZeneca will pay Daiichi Sankyo up […]

Read More

Get In Touch

Let's keep the conversation going